WebEfti’s Mechanism of Action . Efti is a first-in-class antigen presenting cell (APC) activator currently being developed by Immutep for the ... Immutep’s current lead product candidate is eftilagimod alpha (“efti” or “IMP321”), a soluble LAG3 fusion - protein (LAG-3Ig), which is a first-in-class antigen presenting cell (APC ... WebMar 14, 2024 · Immutep CEO, Marc Voigt, said: "With its novel mechanism of action to activate antigen-presenting cells, efti has to date safely improved clinical outcomes from anti-PD-(L)1 therapies and standard ...
IMP321 (Eftilagimod Alpha) as Adjunctive to a Standard …
WebEftilagimod alpha (IMP321), a soluble dimeric recombinant form of LAG-3, is a first-in-class antigen presenting cell activator under clinical development. By stimulating … WebImmutep is investigating its novel efti immunotherapy and its distinctive mechanism of action across numerous solid tumor indications in combination with anti-PD-(L)1 therapies, chemotherapy, and as part of a … family care office
Initial results from a Phase II study (TACTI-002) of eftilagimod …
Web3 Candidate Eftilagimod Alpha (Efti) in Soft Tissue Sarcoma • Expansion of the efti clinical development pipeline with a new Phase II setting • Efti Phase II trial awarded €1.5M (~A$2.2M) in funding as part of the Polish Medical Research Agency ... Efti’s novel mechanism of action offers potential to enhance anti- WebNov 11, 2024 · Iams W, Felip E, Majern M, et al. Combining the antigen-presenting cell activator eftilagimod alpha (soluble LAG-3) and pembrolizumab: efficacy results from the 1st line non-small cell lung cancer ... WebEftilagimod alpha is a large-molecule cancer drug being developed by the clinical-stage biotechnology company Immutep. Efti is a soluble version of the immune checkpoint molecule LAG-3. It is an APC Activator used to increase an immune response to tumors, and is administered by subcutaneous injection. family care of hartford ct